What is Alopecia Areata?
Alopecia areata is a chronic, autoimmune skin disorder characterized by sudden, non-scarring hair loss. It typically presents as well-defined, smooth patches of hair loss on the scalp or any hair-bearing area of the body.
Origin of the disease
The condition results from an immune-mediated disruption of the normal hair cycle, where the immune system attacks hair follicles, leading to hair shedding and impaired regrowth. Alopecia areata can affect individuals of any age or ethnicity.
Beyond the physical symptoms, the disease often has a significant psychological impact and can negatively affect quality of life due to its unpredictable course. Current treatment options are limited and do not always provide sustained hair regrowth, highlighting the need for new therapeutic approaches.
Conditions of participation:
age 18-50
diagnosed with severe alopecia areata involving 50–90% of the scalp
duration of the current episode is 6 months to 4 years
no significant spontaneous hair regrowth within the last 6 months
willingness not to use other treatments for alopecia areata during the study
agree to undergo skin biopsies during the study
We provide participants with
comprehensive health assessment
(including: dermatological examination and assessment of the degree of hair loss, screening tests for selected infections, photographic documentation of changes, ECG, chest X-ray and extended blood and urine tests)
access to innovative treatment
ongoing medical care throughout the study period
You can find other benefits of participating in a clinical trial on the “What are clinical trials?” tab.
Study duration
The total study duration is approximately 48 weeks, including:
• Screening period: up to 5 weeks,
• Treatment period: 24 weeks,
• Follow-up period: 19 weeks after the last treatment visit.
Join us!
Form
Principal Investigator
dr n. med. Justyna Kwapisz
